Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Journey Medical (DERM) EBITDA Margin: 2020-2025

Historic EBITDA Margin for Journey Medical (DERM) over the last 5 years, with Sep 2025 value amounting to -8.67%.

  • Journey Medical's EBITDA Margin rose 1111.00% to -8.67% in Q3 2025 from the same period last year, while for Sep 2025 it was -9.25%, marking a year-over-year increase of 2193.00%. This contributed to the annual value of -24.36% for FY2024, which is 2175.00% down from last year.
  • Per Journey Medical's latest filing, its EBITDA Margin stood at -8.67% for Q3 2025, which was up 54.74% from -19.16% recorded in Q2 2025.
  • Over the past 5 years, Journey Medical's EBITDA Margin peaked at 49.93% during Q3 2023, and registered a low of -90.02% during Q2 2021.
  • Moreover, its 3-year median value for EBITDA Margin was -19.70% (2024), whereas its average is -21.85%.
  • As far as peak fluctuations go, Journey Medical's EBITDA Margin slumped by 7,813bps in 2021, and later skyrocketed by 10,883bps in 2023.
  • Journey Medical's EBITDA Margin (Quarterly) stood at -51.70% in 2021, then tumbled by 1,090bps to -62.60% in 2022, then spiked by 4,881bps to -13.79% in 2023, then spiked by 3,019bps to 16.40% in 2024, then soared by 1,111bps to -8.67% in 2025.
  • Its EBITDA Margin was -8.67% in Q3 2025, compared to -19.16% in Q2 2025 and -25.30% in Q1 2025.